Quality, Affordable and Accessible

Sinophi signs China and SE Asia distribution deal with Advanced Oncotherapy for its proton treatment systems

On March 25^th 2015 Sinophi signed an exclusive 15-year agreement with Advanced Oncotherapy to be the company’s first tier distributor for the LIGHT proton system for cancer treatment in China and other countries in SE Asia.  Advanced Oncotherapy is a UK company based in London and develops next-generation proton therapy systems for cancer treatment.

Advanced Oncotherapy’s team based at CERN (European Centre for Nuclear Research) in Geneva focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit whose cost and size are significantly below industry standards. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older cancer treatment technologies.

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology derived from its ADAM subsidiary (Application of Detectors and Accelerators to Medicine), a CERN-spinout which AVO acquired in 2007.  As a result, Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

The size of the cancer treatment challenge in China and the opportunity for Sinophi and Advanced Oncotherapy is illustrated by data from the World Health Organisation’s “World Cancer Report”.  In 2012, China had 3.07 million newly diagnosed cancer cases, 21.8% of the world total.  China also had 2.2 million or 26.9% of the world’s total cancer deaths.  The report states China registered the most new cancer cases and deaths from four types of malignant cancer: liver, oesophagus, stomach and lung.

Commenting on the agreement, Sanjeev Pandya, CEO of Advanced Oncotherapy said:  “We are delighted to have teamed up with Sinophi Healthcare in China and Southeast Asia.  Sinophi brings its experience as an investor and manager of public hospitals in China and a decade of work on hospital projects around Southeast Asia.  We look forward to working with Sinophi to bringing Advanced Oncotherapy’s LIGHT proton beam system for cancer treatment to many hospitals in China and Southeast Asia.” 

Commenting on the agreement, Hanif Kanji, CEO of Sinophi said: “We are very excited to be working with Advanced Oncotherapy to bring this cutting edge LIGHT system to China and Southeast Asia.  AVO’s system is substantially lower in cost compared to current technology and it delivers performance advantages in treating a variety of cancer conditions.  Our work with Advanced Oncotherapy and its pioneering proton treatment technology fits very with Sinophi’s partnerships with and investments in public hospitals. We are committed to making the best treatments available and affordable to all patients.”

Commenting on the agreement, Simon MacKinnon, Chairman of Sinophi said: “Tackling rising rates of cancer and improving cancer patient survival rates is a top priority for the governments and health systems of China and the countries of Southeast Asia.  With public healthcare system budgets under great pressure everywhere, Sinophi and Advanced Oncotherapy’s world-leading proton beam cancer treatment system will save China and Southeast Asian countries billions of dollars over the next decade in treating cancer.”

About Advanced Oncotherapy Plc  (www.avoplc.com)

Advanced Oncotherapy is a UK company and developer of next-generation proton therapy systems for cancer treatment.  It is listed on AIM on the London Stock Exchange (stock symbol: AVO). Its LIGHT machine systems greatly reduce the cost of proton beam therapy for cancer treatment and bring it within reach of many more patients.

About Sinophi Healthcare  (www.sinophi.com)

 Sinophi Healthcare is a UK company investing in and managing hospitals in China, focused on public general and specialty hospitals.  Sinophi works in partnership with hospitals in China’s rapidly growing urban areas to deliver improvements in the delivery of healthcare. Sinophi brings to hospitals in China international hospital expertise, links with hospitals in the UK’s National Health Service system and partnerships with leading UK and international healthcare service and product partners.